Skip to main content

Table 2 A priori defined secondary and tertiary outcome measures

From: Assessment of safety and efficacy of mesenchymal stromal cell therapy in preclinical models of acute myocardial infarction: a systematic review protocol

Outcomes Comments and/or Examples of specific measures
Secondary outcomes:
 Death Rarely used an outcome due to ethical concerns regarding animal welfare
 Infarct size Variety of quantifiable techniques (e.g. histological staining, nuclear imaging)
 Cardiac function Echocardiography
◦ cardiac output
◦ left ventricle end diastolic diameter
◦ left ventricle end systolic diameter
◦ fractional shortening
Cardiac catheterization
◦ cardiac output
◦ left ventricular end diastolic pressure
◦ left ventricular end systolic pressure
◦ mean pulmonary artery pressure
◦ right atrial pressure
 Biochemical outcomes Proinflammatory cytokines
◦ interleukin-1beta, 6
◦ tumour necrosis factor-alpha
Anti-inflammatory cytokines
◦ interleukin-10
◦ transforming growth factor-beta1, 2, 3
 Vessel density Histological staining and quantification of vessels in cardiac tissue
Tertiary outcomes:
 Cellular retention Imaging and quantification of labelled cells in host tissue
 Cellular differentiation Measurement of cardiac troponin in donor cells retained in host tissue